Abstract
Personalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to immune-related adverse events. Understanding the role of germline genetic factors in determining individual responses to immunotherapy will deepen our understanding of immune toxicity and, importantly, it may lead to tools for identifying patients who are at risk.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents, Immunological / adverse effects*
-
Antineoplastic Agents, Immunological / therapeutic use
-
Genetic Testing / methods*
-
Genome-Wide Association Study / methods*
-
Humans
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / immunology
-
Precision Medicine / methods*
-
Receptors, Immunologic / antagonists & inhibitors*
-
Receptors, Immunologic / genetics
Substances
-
Antineoplastic Agents, Immunological
-
Receptors, Immunologic